PBL Therapeutics

PBL Therapeutics was a clinical-stage biotechnology company dedicated to developing novel interferon-based therapies for oncology and infectious diseases. Founded by Dr. Sidney Pestka, a seminal figure in interferon research, the company focused on engineering "super-interferons" with enhanced biological activity and reduced side effects. Its lead candidate, PBL-1001, was a long-acting interferon alpha designed to improve patient outcomes in chronic viral hepatitis and various solid tumors. Although the company is no longer active, its legacy continues through its sister organization, PBL Assay Science, which remains a leading provider of cytokine-related research products. The company's approach combined deep expertise in protein structure-function relationships with advanced recombinant DNA technology.